GC Asp432Glu

Vitamin D Binding Protein — The Carrier That Shapes Your Vitamin D Status

Vitamin D travels through your bloodstream bound to a carrier protein called
VDBP | Vitamin D binding protein, also known as group-specific component (GC), carries approximately 85-90% of circulating 25(OH)D and 85% of 1,25(OH)2D in the blood
(vitamin D binding protein). Roughly 85-90% of the vitamin D in your blood is
bound to VDBP, making it the single largest determinant of how vitamin D is
transported to tissues, how long it remains in circulation, and how much is
available for cellular uptake. The rs7041 variant in the GC gene changes a
single amino acid in this carrier protein, creating isoforms with different
binding properties that measurably affect your vitamin D levels.

The Mechanism

The rs7041 variant produces a missense change | A missense variant changes one amino acid to another in the protein sequence
at position 432 of the VDBP protein: aspartic acid (Asp) in the reference form
and glutamic acid (Glu) in the alternate form. Together with a second variant
in the same gene (rs4588 | The companion GC variant at codon 436, where Thr defines Gc1 and Lys defines Gc2),
rs7041 defines the three major VDBP isoforms that differ in binding affinity
and glycosylation:

• Gc1f (rs7041-A + rs4588-C): highest binding affinity for 25(OH)D
• Gc1s (rs7041-C + rs4588-C): intermediate binding affinity
• Gc2 (rs7041-A + rs4588-A): lowest binding affinity

The Gc1f isoform (A allele at rs7041) binds vitamin D metabolites most tightly.
This means more total vitamin D is protein-bound and less circulates as
free 25(OH)D | The unbound fraction of vitamin D that can enter cells directly without receptor-mediated uptake; represents about 0.03% of total circulating 25(OH)D.
Paradoxically, individuals with the highest-affinity carrier (AA genotype) tend
to have the lowest levels of free, bioavailable vitamin D despite potentially
adequate total levels.

The isoforms also differ in glycosylation patterns that affect conversion to
Gc-MAF | GC protein-derived macrophage activating factor, an immune modulator produced by enzymatic modification of VDBP that activates macrophages.
Gc1 isoforms are more efficiently converted to Gc-MAF than Gc2, with
implications for innate immune function.

The Evidence

A landmark GWAS of 4,501 Europeans | Ahn J et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet, 2010
identified rs7041 as a genome-wide significant determinant of circulating
25(OH)D concentrations (P = 4.1 x 10^-22). A subsequent
GWAS focused on VDBP levels | Moy KA et al. Genome-wide association study of circulating vitamin D-binding protein. Am J Clin Nutr, 2014
found even stronger association: mean serum DBP concentrations were 7,335,
5,149, and 3,152 nmol/L for individuals carrying 0, 1, and 2 copies of the
minor allele respectively (P = 1.42 x 10^-246).

A study in women across reproductive states | Ganz AB et al. Vitamin D binding protein rs7041 genotype alters vitamin D metabolism in pregnant women. FASEB J, 2018
found that AA (TT on coding strand) carriers had 25(OH)D levels at 80% of CC
(GG) carriers (P = 0.05), but paradoxically had 2.5 times higher free 25(OH)D
(P < 0.0001). This reflects lower VDBP concentrations with the A allele,
resulting in less total binding but more unbound vitamin D available for
cellular uptake.

A supplementation study in 234 vitamin D-deficient adults | Al-Daghri NM et al. Efficacy of vitamin D supplementation according to vitamin D-binding protein polymorphisms. Nutrition, 2019
found that homozygous A allele carriers were 6.2 times more likely to remain
deficient after supplementation, and heterozygotes 4.2 times more likely,
compared to CC homozygotes (P < 0.001). This makes rs7041 one of the
strongest genetic predictors of vitamin D supplementation response.

In a cohort of 414 smokers | Janssens W et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax, 2010,
AA homozygotes had a 25% reduction in 25(OH)D levels and an increased risk
for COPD (OR 2.11, 95% CI 1.20-3.71, P = 0.009).

Practical Implications

The key insight from rs7041 is the distinction between total and free vitamin D.
Standard blood tests measure total 25(OH)D, which is heavily influenced by VDBP
levels. If you carry the A allele, your total vitamin D may appear low on
standard testing even when your free (bioavailable) vitamin D is adequate. This
matters because clinical decisions about supplementation are usually based on
total 25(OH)D.

AA carriers should consider testing both total and free 25(OH)D if available,
may need higher doses to reach standard target levels on total 25(OH)D, and
should take vitamin D3 with fat-containing meals for optimal absorption.
Consistent daily dosing (e.g. 2,000-4,000 IU daily) may work better than
large intermittent doses for genotypes with altered VDBP kinetics.

Interactions

rs7041 interacts directly with rs4588 in the same gene to determine the three
VDBP isoforms (Gc1f, Gc1s, Gc2). The combination of both variants provides
more information than either alone. rs7041-A with rs4588-A creates the Gc2
isoform (lowest binding affinity), while rs7041-A with rs4588-C creates
Gc1f (highest affinity). This means the same rs7041 genotype can have
different functional consequences depending on rs4588 status.

rs7041 also interacts with VDR (rs1544410) and CYP2R1 (rs10741657). If VDBP
transport is impaired (rs7041 AA) alongside reduced vitamin D activation
(CYP2R1 AA) or reduced receptor sensitivity (VDR TT), the combined effect
on vitamin D status is compounded. These multi-gene interactions are
addressed in compound implications when all relevant genotypes are present.